Work

Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study

Year: 2025

Type: article

Abstract: Aims The prevalence of type 2 diabetes has increased in France over the past decade, with changes in available pharmacologic treatments. This study aimed to assess trends in the sales of antidiabetic drugs in France over the last decade. Methods This retrospective cohort study used data from French national health insurance databases. Defined daily doses per 1000 inhabitants per day (DDD/TID), expenditures associated, and the proportion of the population receiving treatment were analyzed from January 2013 to December 2022. Results Between 2013 and 2022, the proportion of patients purchasing at least one antidiabetic drug per month increased from 3.07% to 4.12%, with average monthly consumption rising from 82.62 to 101.68 DDD/TID. Biguanides were the most sold antidiabetic drug, followed by sulfonylureas and insulin. The greatest increases in consumption and expenditures were observed for GLP-1 analogs and SGLT2 inhibitors. Conclusion The consumption and cost of antidiabetic drugs increased with the diabetes prevalence. GLP-1 analogs and SGLT2 inhibitors accounted for the main growth, reflecting their growing clinical adoption and evidence of efficacy, while sales of sulfonylureas and DPP4 inhibitors remained substantial despite concerns regarding their benefit-risk profiles. In 2022, expenditures for GLP-1 analogs surpassed insulin. These findings have implications for healthcare policy and resource allocation planning.

Source: Clinical Therapeutics

DOI: 10.1016/j.clinthera.2025.02.005

Authors: De Bandt David, Johanna Mezence, Claire Rives Lange, Dominik Menges, Claire Carette